Objective: A highly sensitive thyroglobulin assay (Elecsys ® Tg II, Roche Diagnostics, Penzberg, Germany) has become available for monitoring patients with differentiated thyroid cancer (DTC). Here, we evaluated the clinical performance of Elecsys ® Tg II assay in a multicentre patients series and compare it with the established Access ® Tg assay (Beckman Coulter, Brea, CA, USA).
| INTRODUCTION
Differentiated thyroid carcinoma (DTC) has a favourable outcome in most patients and a 10-year survival rate ranging from of 80%-95%. [1] [2] [3] Standard primary treatment includes thyroidectomy, risk-adapted radioiodine (I-131) ablation and lifelong therapy with levothyroxine (LT4). 1, 4 Recurrences may occur in 10%-20% of patients, mostly within 5 years after primary treatment. 2, 5 The mainstays of follow-up are serum thyroglobulin (Tg) measurement and neck ultrasonography (US). 3, 4 Nowadays, highly sensitive assays (ie functional sensitivity [FS] ~0.1-0.2 μg/L) prompt monitoring Tg without any TSH stimulation, saving economic resources and ameliorating patients' comfort. [6] [7] [8] [9] [10] [11] [12] [13] Recent clinical guidelines define an excellent response to treatment when negative imaging and high-sensitive Tg levels <0.1-0.2 μg/L are obtained 6-12 months after primary treatment. 2 Notably, the majority of literature data were obtained by using the Tg Access ® assay (Beckman Coulter, Fullerton, CA, USA). 8 However, different Tg levels may be obtained when the same serum is measured on different assays. 2, [11] [12] [13] Accordingly, assay-specific cut-offs and clinical decision limits should be defined and provided by manufacturer and verified locally by laboratories providing Tg measurement for DTC follow-up.
12
Recently, a new fully automated highly sensitive Tg assay has become available (Elecsys ® Tg II, Roche Diagnostics, Rotkreuz, Switzerland). To date, this assay has not been compared with other highly sensitive assays in a large clinical cohort of DTC patients. Therefore, the aims of this study were (i) to evaluate the diagnostic performance of Elecsys ® Tg II assay and (ii) to compare it with the well-established Access ® Tg assay in a large multicentre series of well-characterized, prospectively selected, DTC patients.
| PATIENTS AND METHODS

| Patients, samples, study design and reference standard
Four institutions participated in this study: Ente Ospedaliero Cantonale (Bellinzona, Switzerland), Ospedale Galliera (Genova, Italy), University of Messina (Messina, Italy) and University of Torino (Torino, Italy). At our centres, DTC patients, excepting those with unifocal DTC <1 cm in the largest diameter, undergo total thyroidectomy with central or lateral neck dissection, depending on risk and intra-operative findings, and a subsequent radioiodine ablation (RRA) according to the European Association of Nuclear Medicine (EANM) recommendations. 14 Three to seven days after RRA, a post-treatment whole-body scan (PT-WBS) is performed. Overall, based on pre-operative assessment, intra-operative findings, pathology report and PT-WBS results, patients are classified at high-, intermediate-or low-risk. 2 The medical records of all DTC patients diagnosed, treated and followed up since January 2005 in the above institutions (n = 1456; Bellinzona n = 326, Genova n = 397, Messina n = 372, Torino n = 361) were reviewed to extract a standardized data set (ie demographic data, surgical and pathological report, follow-up reports, whole-body scan and ultrasound reports and laboratory data). Patients were then enrolled into this study if: (i) they underwent a (near-) total thyroidectomy (and, on indication, central neck lymph node dissection) resulting in apparent complete resection of neoplastic foci (R0); (ii) they received I-131
for thyroid remnant ablation and the corresponding post-treatment whole-body scan (PT-WBS) showed no foci of I-131 uptake outside the thyroid bed; (iii) they received LT4 treatment, and TSH levels were maintained below 0.1-0.5 mIU/L (depending on risk stratification) until the early follow-up visit (ie 6-12 months after ablation); (iv) they tested negatively for TgAb in local methods; (v) they underwent serum
Tg measurement before and after recombinant human TSH (rhTSH) stimulation 6-12 months after ablation, and residual serum samples >0.5 mL were available; (vi) their serum samples were stored at −80°C
and had undergone no more than 1 freeze/thaw cycle. The disease-free survival (DFS) was calculated from the date of radioiodine ablation to the date of last follow-up (NED patients) or the date of relapse detection (bREC and sREC patients).
| Laboratory
During the study period, different Tg and TgAb assays were employed in different centres (Table S1 ). Once the study was com- The total CV of serum Tg was 3.9% for pooled serum from healthy subjects and 4.4%-5.6% in low-, middle-and high-level controls.
Linearity was observed in serum Tg at the tested concentrations from 0 to 470 μg/L. Functional sensitivity was determined using the 20% CV between-run precision. (CV) at these different Tg concentrations was 9.5%, 2.5%, 2.5% and 2.5%, respectively. In a similar study, Kwon and colleagues
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found a total precision of 9.6% and limit of detection (LOD) and FS both at 0.04 μg/L. Additionally, we participated in multicentre 
| Statistical analysis
The relationship between Tg assays was assessed and the Pearson correlation coefficient (r) calculated. Bland-Altman plot analysis was used to assess the agreement between Tg assays; 24 the difference between the results of the 2 assays was plotted against the average, 
| Ethics
The protocol was approved by the Ethics Committee of Canton Ticino (Switzerland) and Clinical Research Committees of each participating centre. All patients gave their informed consent before participating in the study. 
| RESULTS
| Patient characteristics and general results
| Comparison of Tg assays
| Correlation between basal and rhTSHstimulated Tg results
Basal and rhTSH-Tg values were significantly correlated (P < .0001) using both assays. 
| Performance of basal and rhTSH-stimulated Tg in detecting structural cancer relapse
Basal and stimulated Tg results at first follow-up visit were compared with the clinical status of patients over time. At ROC curve analysis (Figure 1) , the most accurate cut-off of basal Tg to predict cancer relapse was 0.41 μg/L for Elecsys ® Tg II and 0.36 μg/L for Access ® assay. By using these thresholds, sensitivity, specificity, PPV, NPV and accuracy (with attached 95% CI) of basal Tg were 100% (98%-100%), 96% (92%-98%), 79% (63%-89%), 100% (98%-100%), 98%
(92%-100%) for Elecsys ® and 100% (98%-100), 96% (92%-98%), 79% (63%-89%), 100% (98%-100%), 98% (92%-100%) for Access ® ,
respectively. The performance of rhTSH-Tg to predict sREC was also analysed, and the optimal thresholds were 1.82 μg/L for Elecsys ® Tg II and 1.62 μg/L for Access ® Tg assay, with corresponding sensitivity, specificity, PPV, NPV and accuracy of 100% (98%-100%), 95%
(91%-98%), 73% (54%-88%), 100% (98%-100%) and 96% (90%-99%)
for Elecsys ® and 100% (98%-100%), 95% (91%-98%), 73% (54%-88%), 100% (98%-100%) and 96% (90%-99%) for Access ® , respectively. Discordant results of basal Tg occurred in 2 NED patients (one false positive in Elecsys ® and one in Access ® ). No discrepancy was observed in rhTSH-Tg results.
| Outcome over time (Kaplan-Meyer curves and Cox proportional hazard regression)
The Kaplan-Meier method was used to estimate the DFS of patients with basal and stimulated Tg higher than the above ROC-derived cut-offs. As shown in Figure 2 (Table 3) . Then, the
Cox's multivariate model included basal Tg (with separate analysis for Elecsys ® and Access ® ) and the above clinico-pathological parameters.
The basal Tg was the only independent predictor of cancer relapse (Table 3) . Looking at large 95% CI of both HRs, one might argue the models had Multivariate model did not include stimulated Tg due to its close correlation with basal Tg. Age at diagnosis was initially dichotomized, and the most accurate cut-off was >55 y with 77.3% sensitivity and 59% specificity. In addition, age was evaluated as continuous variable and did not show significant HR (1.04, 95% CI from 0.98 to 1.07); TNM staging was also analysed as stages III-IV vs I-II and no significant HR was found (1.83, 95% CI from 0.74 to 4.52).
low power; this is likely due to the low number of recurrences we reported in our series, as certainly expected in DTC patients treated by thyroidectomy and radioiodine ablation. However, even in the worst scenario, a positive basal Tg value confers a significantly higher probability of cancer relapse than a negative one. That is extremely relevant for patients' management.
Strengths of our study are the relatively large number of patients, the homogeneous treatment and follow-up protocols with uniform diagnostic methods, risk-assessment and dynamic risk stratification criteria. Indeed, only patients treated with radioiodine ablation were included, avoiding the presence of Tg-secreting thyroid tissue remnants as a confounding factor. Some potential limitations should be also addressed; first, while consecutive patients were enrolled and prospectively managed, the performance of Elecsys ® Tg II and Access ® Tg assays was evaluated by post hoc analysis. However, Tg levels measured by both methods were not taken into account in clinical management and, consequently, relevant biases are unlikely.
Second, considering the retrospective patients' enrolment, a selection bias cannot be completely excluded. However, clinical practice in our centres is homogeneous and strict enrolment criteria were adopted making a significant effect unlikely. Third, the effects of freezing and prolonged storage were not assessed in the present study. Previous studies, however, excluded significant effects of prolonged serum storage, freezing and thawing on Tg and TgAb measurement. 30, 31 Fourth, the period of postoperative follow-up of our patients might not be considered as long enough; nevertheless, recurrences have previously been reported to be rare in patients, including those at higher risk, achieving excellent response after thyroid ablation and most relapses occur early during follow-up [2] . Therefore, no significant bias might be expected.
| CONCLUSIONS
The Elecsys ® Tg II and Access ® Tg assays cannot be used interchangeably due to insufficient analytical agreement. However, using ROC-derived assay-specific cut-offs, the diagnostic and prognostic performance of Elecsys ® Tg II assay was comparable to that of the well-established Access ® Tg assay.
